Atypical Reversible Leucoencephalopathy Syndrome after Bevacizumab/Folfox Regimen for Metastatic Colon Cancer. (21st October 2014)

• Record Type: Journal Article
• Authors: Salmi, Narimane; Elghissassi, Ibrahim; Bellahammou, Khadija; Lakhdissi, Asmaa; Mrabti, Hind; Errihani, Hassan
• Other Names: Aksoy Sercan Academic Editor.
• Is Part Of: Case reports in oncological medicine. Volume 2014(2014)
• Publication Date: 2014-10-21
• Subjects: Oncology -- Periodicals; Tumors -- Periodicals; Oncology -- Case studies -- Periodicals; Neoplasms; Oncology; Tumors; Electronic journals; Periodicals; Case studies; Periodicals; Case Reports; Fulltext; Internet Resources; Periodicals; 616.994
• DOI: 10.1155/2014/391256
• Languages: English
• ISSNs: 2090-6706

Abstract

Abstract : We are reporting a case of multifocal reversible leucoencephalopathy syndrome induced by chemotherapy based on Folfox-Bevacizumab regimen. A 44-year-old female, with no history of hypertension, received a chemotherapy based on Folfox-Bevacizumab for her metastatic colon cancer (5 FU: 325 mg/m 2 d1 by intravenous infusion, Oxaliplatin 80 mg/m 2 d1, and Bevacizumab: 7.5 mg/Kg d1). During the fourth cure, she presented delirium, seizures, and visual disturbances. The computed tomography (CT) of the brain showed hypodense lesions of the white matter of frontal, parietal, and occipital lobes, which were bilateral and symmetrical. The clinical table was reversible under symptomatic treatment.